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David N. Campbell, MD, Max B. Mitchell, MD, Suzanne Osorio da Cruz, DVM,
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Objectives We sought to analyze the indications and outcome of extracorporeal membrane oxygenation (ECMO) for early
primary graft failure and determine its impact on long-term graft function and rejection risk.
Background Early post-operative graft failure requiring ECMO can complicate heart transplantation.
Methods A retrospective review of all children requiring ECMO in the early period after transplantation from 1990 to 2007
was undertaken.
Results Twenty-eight (9%) of 310 children who underwent transplantation for cardiomyopathy (n  5) or congenital
heart disease (n  23) required ECMO support. The total ischemic time was significantly longer for ECMO-
rescued recipients compared with our overall transplantation population (276  86 min vs. 242  70 min, p 
0.01). The indication for transplantation, for ECMO support, and the timing of cannulation had no impact on sur-
vival. Hyperacute rejection was uncommon. Fifteen children were successfully weaned off ECMO and discharged
alive (54%). Mean duration of ECMO was 2.8 days for survivors (median 3 days) compared with 4.8 days for non-
survivors (median 5 days). There was 100% 3-year survival in the ECMO survivor group, with 13 patients (46%)
currently alive at a mean follow-up of 8.1  3.8 years. The graft function was preserved (shortening fraction 36
 7%), despite an increased number of early rejection episodes (1.7  1.6 vs. 0.7  1.3, overall transplant pop-
ulation, p  0.05) and hemodynamically comprising rejection episodes (1.3  1.9 vs. 0.7  1.3, overall trans-
plant population, p  0.05).
Conclusions Overall survival was 54%, with all patients surviving to at least 3 years after undergoing transplantation. None of
the children requiring 4 days of ECMO support survived. Despite an increased number of early and hemody-
namically compromising rejections, the long-term graft function is similar to our overall transplantation
population. (J Am Coll Cardiol 2009;54:730–7) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.062(
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(eart transplantation in children with end-stage heart
ailure secondary to cardiomyopathy or failed palliation of
ongenital heart disease (CHD) is a good option with
mproving outcomes (1). One of the most common com-
lications in the immediate period after transplantation is
arly graft failure. Graft failure can result from long isch-
mic time, inadequate myocardial preservation at time of
rocurement, hyperacute rejection, or poor adaptation of
he graft to the recipient’s hemodynamic environment (2).
ither as a consequence of left heart failure or as a result of
ingle ventricle physiology, pulmonary vascular resistance
rom the Children’s Hospital of Denver, Aurora, Colorado. Dr. Ivy is a consultant for
ctelion, United Therapeutics, and Gilead.o
Manuscript received February 24, 2009; revised manuscript received April 13,
009, accepted April 20, 2009.PVR) in many pediatric recipients is increased, resulting in
he risk of right ventricular failure after transplantation.
See page 738
easures aimed at decreasing PVR after transplantation
nclude the use of inhaled nitric oxide as well as medications
ith pulmonary vasodilator effects, such as prostacyclin,
soproterenol, and milrinone (3). Graft ventricular function
s also commonly supported post-operatively with inotropes
e.g., dopamine, dobutamine, low-dose epinephrine, or
ilrinone). However, despite these interventions, ventricu-
ar failure may persist, and mechanical circulatory support
ecomes necessary. Extracorporeal membrane oxygenation
ECMO) is widely used for post-cardiotomy low cardiac
utput syndrome (LCOS) in children and is occasionally
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August 18, 2009:730–7 ECMO for Primary Graft Failure in Childrenequired after pediatric heart transplantation (4–6). The
bjectives of this study were as follows: 1) to describe the
ndications and outcome of ECMO for early primary graft
ailure after heart transplantation in children; 2) to identify
arkers predictive of ECMO survival in this patient pop-
lation; and 3) to determine the impact of early ECMO on
ong-term graft function and rejection risk.
ethods
ransplantation. We reviewed our institutional heart
ransplant database from 1990 to 2007. After approval by
ur institutional review board, all children requiring
CMO in the post-operative transplantation period were
ncluded in the study. The course after transplantation for
ll eligible patients was reviewed. Our institutional trans-
lantation methodology has been previously described but
ill be reviewed here (7). Donor hearts are procured in
tandard fashion, with great vessel lengths harvested as
etermined by recipient anatomy. Roe’s solution is used for
onor cardioplegia. One of the ECMO-rescued recipients
ho survived underwent transplantation from a nonbeating
eart donor. Organ procurement in the setting of donation
fter cardiac death has been previously described by our
roup (8). All of the other patients underwent transplanta-
ion from standard brain-dead, heart-beating donors.
oreover, there were no changes in our procurement
ractices throughout the duration of this study period.
Milrinone, dopamine, isoproterenol, and occasionally
pinephrine are commonly used for inotropic support in the
mmediate post-transplantation period. Nitric oxide is sys-
ematically used in patients with an elevated PVR docu-
ented before transplantation (PVR 5 Wood units/m2).
riple immunosuppression with methylprednisolone for
8 h, low-dose cyclosporine, and azathioprine is used
erioperatively. Induction therapy with methylprednisolone
nd antithymocite globulin (Thymoglobulin, Genzyme
orp., Cambridge, Massachusetts) was used until 1998, at
hich time Thymoglobulin was replaced by antithymocyte
lobulin (American Medical Resources, Nashville, Tennes-
ee). Low-dose cyclosporine (target level 40 to 70 ng/ml)
nd azathioprine were administered throughout induction.
t discharge, maintenance immunosuppression consisted of
yclosporine (target level 175 to 225 ng/ml) and mycophe-
olate mofetil (target level 2 to 4 g/ml) (9). In patients
ith an open chest or dependent on mechanical support
ECMO), induction therapy was withheld until chest clo-
ure and/or decannulation was achieved because of the
ncreased risk of infection.
CMO. A standardized ECMO circuit was used with
ppropriately sized cannulas according to the patient size
6). No other types of mechanical support devices were used
uring the course of this study. Transthoracic cannulation
hrough an open chest was used in all patients via the right
trium and ascending aorta. Pump flow was regulated
ccording to systemic perfusion, blood pressure tracing, and dystemic and mixed venous oxy-
enation. Inotropic and ventila-
ory supports were weaned as
olerated during ECMO sup-
ort. In patients with poor left
entricular function, venting of
he left atrium or transcatheter
trial balloon septostomy was
erformed for left-sided decom-
ression whenever required. Left
trial decompression was indi-
ated in the setting of inadequate
eft ventricular decompression,
esulting in increased left atrial
ressure and/or pulmonary edema.
ctivated clotting time was main-
ained between 180 and 220 s with
eparin infusion. Hemofiltration was used as required depend-
ng on the renal function and fluid status. Graft function
ecovery was regularly assessed by transthoracic echocardiog-
aphy. Increased inotropic and ventilatory support was used for
eaning off ECMO. Chest closure was usually delayed until
4 to 48 h after decannulation.
utcome measures. Diagnosis of acute graft rejection in
ur institution is based on clinical presentation, echocardio-
raphic or electrocardiographic findings, hemodynamics at
ime of catheterization, and/or endomyocardial biopsy evi-
ence of rejection (10–12). Hemodynamically significant or
ompromising rejection is defined as a rejection episode for
hich the patient required intravenous inotropic support
hile undergoing treatment for rejection. Hyperacute graft
ejection is defined as occurring during the immediate
ost-operative course after transplantation. Early rejection is
efined as an acute graft rejection episode occurring during
he first year after transplantation, and very early rejection
s occurring during the first month after transplantation.
reatment of acute graft rejection includes anti–T-cell
ntibodies (antithymocyte globulin or OKT3) for 7 to 10
ays in combination with steroids (4 doses) and the
dministration of intravenous immunoglobulin per insti-
utional protocol (12). Transplant coronary artery disease
s diagnosed by angiography or intravascular ultrasound
nd is defined as any luminal irregularities or stenosis that
aried from the patient’s previous angiography or intimal
hickening 3 mm according to the Stanford classifica-
ion (13,14).
Outcome was analyzed in 2 groups: 1) those successfully
eaned off of ECMO and discharged alive (survivor group);
ersus 2) those who died while on ECMO or in the
ost-decannulation period (nonsurvivor group). The long-
erm outcome of the ECMO survivors was compared with
ur overall transplant population.
tatistical analysis. Data are presented as mean  SD.
hen the population does not follow a normal distribution,
edian values are given. Intergroup comparison was con-
Abbreviations
and Acronyms
ACT  activated clotting
time
CHD  congenital heart
disease
ECMO  extracorporeal
membrane oxygenation
LCOS  low cardiac output
syndrome
OHT  orthotopic heart
transplantation
PVR  pulmonary vascular
resistance
VAD  ventricular assist
deviceucted with an unpaired Student t test. Comparison of
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ECMO for Primary Graft Failure in Children August 18, 2009:730–7roportion was made with the Fisher exact test. A p value
0.05 was considered statistically significant. Statistical
nalysis was performed by use of the GraphPad Prism
oftware (GraphPad Software Inc., La Jolla, California).
raphs are represented with mean and SDs.
esults
ransplant demographics. From 1990 to 2007, 310 chil-
ren underwent heart transplantation at our institution, and
8 children who underwent transplantation (9%) were
laced on ECMO for post-operative primary graft failure.
hese 28 children underwent transplantation for cardiomy-
pathy (n  5) or complex CHD (n  23) and required
CMO support for LCOS within 48 h of their transplan-
ation. The cardiomyopathy group included 4 patients with
ilated cardiomyopathy and one with restrictive cardiomy-
pathy. The CHD group comprised 19 infants with hypo-
lastic left heart syndrome variant and 4 children with other
orms of complex CHD. Six of the CHD patients had
revious failed corrective or palliative heart surgery, whereas
7 were referred for transplantation as the primary thera-
eutic option. Patients’ ages ranged between 1 week and
9.5 years (mean 1.3  3.7 years, median 0.3 years).
wenty-four (86%) patients were infants (1 year) at the
ime of transplantation. Weight ranged from 3 to 70 kg
mean 7.8  12.5 kg, median 4.5 kg). This population did
ot follow a normal distribution because of a preponderance
f infant recipients.
ndications for ECMO. Three of the 28 patients were on
CMO for cardiac failure before transplantation (1 survi-
or, 33%). Extracorporeal membrane oxygenation was
tarted in the operating room because of the inability to
ean from cardiopulmonary bypass in 16 patients (8 survi-
ors, 50%), whereas the remaining 12 required ECMO in
he first 48 h after transplantation (7 survivors, 58%) and
ere cannulated in the cardiac intensive care unit. Four
atients had cardiac arrest before ECMO cannulation (4
urvivors, 100%) and of those, 3 developed subsequent
eurological deficits.
ECMO was required for right ventricular failure in 9
atients (5 survivors, 56%) and for biventricular failure in 15
7 survivors, 47%). In the remaining 4 patients, the type of
entricular failure could not be clearly determined from
eview of the records. Only 1 patient was diagnosed with
yperacute rejection as the cause of primary graft failure.
his patient’s graft function did not improve with standard
ejection treatment, and the patient subsequently died from
emorrhagic complications 7 days after initiation of ECMO
upport. One survivor required 4 days of ECMO support,
rom which he was successfully weaned, but then he
eveloped hemodynamically significant rejection at 6 days
fter transplantation and required inotropic support. This
atient had complete recovery of graft function after treat-
ent of this rejection episode and was eventually dischargedome. futcome of ECMO. When comparing the survivor group
ith the nonsurvivor group, we found no significant differ-
nce in the time on the waiting list, age at transplantation,
eight of the recipient, donor/recipient weight ratio, total
schemic time, sex, or blood type distribution between the 2
roups (Table 1). The proportion of infants 1 year of age
as not significantly different between the 2 groups (87% of
urvivors were infants vs. 85% of nonsurvivors, p  0.64).
here was no statistical difference in the survival rate for the
ardiomyopathy group (2 of 5, 40%) compared with the
HD group (13 of 23, 56%, p  0.42). Among the CHD
roup, the survival rate was also not statistically different for
nfants with hypoplastic left heart syndrome (11 of 19, 58%)
ompared with patients with other congenital heart defects
2 of 5, 40%, p  0.41).
There was no significant difference in the proportion of
atients with previous heart surgery and sternotomy before
ransplantation between the survivors (n  3, 20%) and the
onsurvivors (n  3, 23%, p  0.6). The donors’ ejection
raction was significantly lower in the survivor group (65 
%, survivors vs. 71  3%, nonsurvivors, p  0.004), and
lthough the difference in shortening fraction did not reach
statistically significant level, there was a trend toward
ower shortening fraction in the survivor group (32  5%,
urvivors vs. 41  4%, nonsurvivors, p  0.08). There was
trend toward greater peak creatinine (1.3  0.7 mmol/l,
urvivors vs. 1.7  1 mmol/l, nonsurvivors, p  0.1) and
actate (10.1  4.5 mmol/l, survivors vs. 13.4  5.7
mol/l, nonsurvivors, p  0.19) while on ECMO in the
onsurvivor group, but these levels did not reach statis-
ical significance.
Fifteen children were successfully weaned off of ECMO
nd discharged (54%), whereas 13 patients died (46%) of
ersistent heart failure (n  9), diffuse bleeding (n  3),
nd/or sepsis (n  4) at a mean time of 9 days (median 7
ays) after transplantation. Among the deceased patients, 7
ere unable to be decannulated and died at a mean time of
days (median 6 days) from the initiation of ECMO
upport. Six patients were decannulated and died at a mean
ime of 14 days (median 10 days) from the initiation of
CMO support and 10 days (median 6 days) after ECMO
ecannulation. The cause of death in this subset of patients
as mostly related to persistent cardiac failure with end-
rgan dysfunction and subsequent cardiac arrest. One pa-
ient was decannulated after 4 days, experienced persistent
eart failure and multiorgan dysfunction (hepatic and renal
ailure with the need for dialysis), and could not be
esuscitated after cardiac arrest that occurred 37 days after
ransplantation. Mean duration of ECMO was 2.8 days for
urvivors (median 3 days) versus 4.7 days (median 5 days)
or nonsurvivors (p  0.01), with all survivors having been
n ECMO no longer than 4 days (Fig. 1). Mean duration
f ECMO in nonsurvivors weaned off of ECMO was 4 days
median 4.5 days) compared with 5.3 days (median 7 days)
or the nonsurvivors unable to be decannulated (p  0.05).
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August 18, 2009:730–7 ECMO for Primary Graft Failure in Childrenharacteristics of ECMO-rescued recipients. When
omparing the recipients requiring ECMO support for early
ost-operative graft failure (survivors and nonsurvivors
ombined) with our overall transplant population, we found
hat there was a significant difference with a longer total
schemic time (276  86 min vs. 242  70 min, p  0.008)
Fig. 2), a younger age (1.3  3.7 years vs. 4.8  6.4 years,
 0.002), and a smaller weight at transplantation (7.8 
2.6 kg vs. 16.8  18.4 kg, p  0.0001) for the ECMO-
escued patients (Table 2). Indications for transplantation
ata of Surviving Versus Nonsurviving Pediatric Heart Transplantecipients Rescued With ECMO Support for Early Post-Operative GTable 1 Data of S rviving Versus Nonsurv ving Pediatric HeartRecipients Rescued With ECMO Support for Early Post
Survivors of ECMO (n 
Data Mean  SD
Demographics
Recipient weight (kg) 5.6  3.5
Donor weight (kg) 11.7  10.7
Donor/recipient weight ratio 1.9  0.8
Age at OHT (yrs) 0.7  1.4
Infants 1 yr at OHT 13
Male 7
Female 8
Blood type
O 7
A 6
B 1
AB 1
Indication for transplant
Cardiomyopathy 2
CHD all 13
HLHS 11
Past history
Previous sternotomy 3
Transplant
Time waiting (days) 89  69
Total ischemic time (min) 266  91
Donor ejection fraction (%) 65  9
Donor shortening fraction (%) 32  5
ECMO pre-OHT 1
Failure after transplantation
Right ventricular failure 5
Biventricular failure 7
Undetermined cause of failure 3
Pre-ECMO cardiac arrest 4
ECMO
Intraoperative ECMO 8
Post-operative ECMO 7
Peak creatinine on ECMO (mmol/l) 1.3  0.7
Peak lactate on ECMO (mmol/l) 10.1  4.5
ECMO duration (days) 2.8  0.6
ECMO decannulation 15
Survival
3-year 15
Late 13
ignificant values (p  0.05) are indicated in bold.
CHD  congenital heart disease; ECMO  extracorporeal membrane oxygenation; HLHS  hypcardiomyopathy vs. congenital heart disease, p  0.1), the baiting time on the list (81  107 days vs. 77  97 days,
 0.4), and the donor/recipient weight ratio (1.9  1 kg
s. 1.8 0.6 kg, p 0.38) were not different between these
groups of patients.
ong-term outcome. Neurological complications were
ound in 4 of the 15 (27%) survivors, 2 patients remaining
ith permanent neurological impairment and 2 with tran-
ient and resolved seizures. All of the patients with neuro-
ogical disability were emergently cannulated in the cardiac
ntensive care unit, and 3 of these patients had cardiac arrest
ailureplant
rative Graft Failure
Nonsurvivors of ECMO (n  13)
n % Mean  SD Median % p Value
1 10.3  2.5 5.4 0.17
5 9.8  4.4 10.9 0.29
1.9  1 1.8 0.49
2 2  5.2 0.3 0.19
11 85% 0.64
5 38% 0.47
8 62% 0.47
5 38.5% 0.5
5 38.5% 0.5
3 23% 0.5
0 0% 0.5
3 23% 0.42
10 77% 0.42
8 62% 0.42
3 23% 0.6
72  59 59 0.3
279  89 275 0.36
71  3 70 0.004
41  4 40 0.08
2 15% 0.44
4 31% 0.59
8 62% 0.59
1 7% 0.59
0 0% 0.06
8 62% 0.48
5 38% 0.48
2 1.7  1 1.6 0.1
2 13.4  5.7 11.8 0.19
4.7  2.6 5 0.006
% 6 46% 0.001
0 0% —
0 0% —
left heart syndrome; OHT  orthotopic heart transplantation.raft FTrans
-Ope
15)
Media
4.
8.
2
0.
87%
47%
53%
47%
40%
6.5%
6.5%
13%
87%
73%
20%
69
280
62
32
7%
33%
47%
20%
27%
53%
47%
1.
9.
3
100
100%
87%efore cannulation. Overall, there was 100% 3-year survival
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ECMO for Primary Graft Failure in Children August 18, 2009:730–7or the patients successfully weaned off of ECMO and
ischarged. Two of the survivors died at 4.3 and 7.8 years
fter transplantation, respectively: 1 from chronic rejection
nd graft failure and the other from transplant coronary
rtery disease. Thirteen patients (46%) are still currently
live at a mean follow-up of 8.1 3.8 years; 3 are10 years
nd 10 are 5 years after transplantation.
The graft function in surviving patients is normal, with a
ean shortening fraction by echocardiography of 36  7%
nd no patient with a shortening fraction 25%. The mean
jection fraction obtained by cardiac catheterization was
5  10% and the cardiac index by thermodilution was
.5  1.3 l/min/m2. The mean number of very early graft
ejection episodes was not different for the ECMO-rescued
atients compared with our overall transplant population
0.6  0.6 vs. 0.4  0.6, p  0.1). The ECMO survivors
ad an increased number of early rejection episodes (1.7 
.6 vs. 1.0  1.4, p  0.03) and an increased number of
emodynamically compromising rejections (1.3  1.9 vs.
.7  1.3, p  0.04) compared with the overall transplant
opulation (Table 3, Fig. 3). However, there was no
ifference in the mean overall number of acute cellular
ejection episodes between the survivors and the overall
ransplant population (2.9  3 vs. 2.1  2.7, respectively, p
0.18). The incidence of transplant coronary artery disease
as not increased in the ECMO survivors (2 of 15, 13%
ompared with 16% in our overall transplant population,
 NS).
iscussion
arly primary graft failure after heart transplantation in
hildren is associated with significant rates of mortality and
orbidity. Extracorporeal membrane oxygenation is widely
sed and is well established to support circulatory function
n children with post-cardiotomy LCOS (4,15). On the
asis of this experience, ECMO has become a reasonable
Figure 1 Duration of Support for ECMO
Survivors Versus Nonsurvivors
The extracorporeal membrane oxygenation (ECMO) duration for primary
graft failure between ECMO survivors versus nonsurvivors (p  0.01) is shown.ption for early graft failure in children after cardiacransplantation (4,6,16 –19). Ventricular assist devices
VADs) are better suited for patients expected to require
ong-term support; therefore, ECMO remains the most
ommonly used method of mechanical circulatory support
fter cardiac surgery or in the post-transplantation period of
ediatric patients. This article describes the early and late
utcome of ECMO support for early cardiac graft failure in
hildren and represents the largest pediatric experience to
ate.
In our study, primary post-operative graft failure neces-
itating ECMO was not uncommon (9%). The majority of
atients supported with ECMO in this study were infant
ecipients (86% 1 year of age), reflecting the usual distri-
ution of pediatric heart transplantation recipients, with the
ajority of heart transplantations occurring in the1-year-
ld group (1). Nevertheless, pediatric heart recipients re-
uiring ECMO support for early graft failure were signifi-
antly younger (p  0.01) and had a lower weight at
ransplantation (p  0.001) compared with our overall
ransplantation population. Moreover, their total ischemic
ime was significantly longer (p  0.01), indicating that
arvesting technique and time are crucial and that a longer
schemic time is a major risk factor for graft dysfunction.
The indication for ECMO cannulation did not influence
he outcome, and the survival rate was not different in
atients presenting with biventricular compared with iso-
ated right ventricular failure. In addition, the survival rate
as not significantly different for patients with cardiomy-
pathy compared with patients with CHD. Poor donor
raft function has been implicated as a cause of graft
ysfunction after transplantation, but this was not consid-
red different in our study, with no difference in the
hortening fraction obtained by M-mode echocardiography
All Tx ECMO rescued
0
100
200
300
400
p<0.01
276±89
242±70
m
in
u
te
s
Figure 2 Total Ischemic Time of ECMO-Rescued
Versus All Transplant Recipients
Total ischemic time between extracorporeal membrane oxygenation (ECMO)-
rescued recipients compared with our overall transplant population (p  0.01)
is shown. Tx  transplants.
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August 18, 2009:730–7 ECMO for Primary Graft Failure in Childrenetween ECMO survivors and nonsurvivors. Although the
jection fraction, considered less accurate compared with
he shortening fraction when obtained by M-mode echo-
ardiography, was statistically lower in the survivor group,
he mean and median values remain within the normal
imit, rendering this difference difficult to interpret.
The timing of ECMO cannulation was also not predic-
ive of outcome. Survival was not significantly different
etween patients started on ECMO in the operating room
or failure to wean from cardiopulmonary bypass compared
ith those cannulated in the first 48 h after transplantation
or hemodynamic instability or cardiac arrest in the cardiac
ntensive care unit. This is in contradiction to the previous
eport by Galantowicz and Stolar (19), who reported no
hance of survival if the fresh cardiac allograft could not
upport the patient after cardiopulmonary bypass. More-
ver, cardiac arrest before ECMO cannulation was not a
egative predictive factor for survival in our series, and all
atients who had cardiac arrest survived.
This result clearly differs from survival rates of 33% to
3% for those patients who experience cardiac arrest and
hen are placed on ECMO as a bridge to transplantation
18,20 –23). This finding suggests that the donor’s heart
s more likely to recover after cardiac arrest and subse-
uent ECMO support than the failing ventricle of a
erioperative Data of Pediatric Heart Transplant Recipients Rescued Wor Early Post-Operative G aft F ilure Compared W th the OverallTable 2 Perioperative D ta of Pedi tric Heart Transplant Recipiefor Early Post-Operative Graft Failure Compared With
ECMO-Rescued Recipients
(n  28)
Data Mean  SD Med
Demographics
Recipient weight (kg) 7.8 12.6
Donor/recipient weight ratio 1.9 1
Age at OHT (yrs) 1.3 3.7
Total ischemic time (min) 276 89 27
Waiting time (days) 81 107 6
Indication for transplantation
Cardiomyopathy 5 1
CHD 23 8
ignificant values (p  0.05) are indicated in bold.
CHD  congenital heart disease; other abbreviations as in Table 1.
Outcome Data of Survivors Rescued With ECMOPost-Op rative Graft Failure Compared With theTable 3 Outcome Data of Survivors RescuedPost-Operative Graft Failure Compa
Data
Surviv
(
Outcome
TCAD
Rejections
Total 2
Very early (within 30 days of transplantation) 0
Early (within 1 year of transplantation) 1
Hemodynamic compromising 1Values are n (%) or mean  SD. Significant values (p  0.05) are indicated i
TCAD  transplant coronary artery disease; other abbreviations as in Tableatient who is in need of transplantation. Importantly,
owever, emergent cannulation was associated with a
reater risk of neurologic complications, and all survivors
ith neurological sequelae were either cannulated emer-
ently or experienced cardiac arrest before cannulation.
herefore, anticipating graft failure with elective cannu-
ation before hemodynamic collapse is likely to improve
eurologic outcome.
The mean duration of ECMO support in survivors was
ignificantly less than nonsurvivors, and all survivors were
ecannulated within 4 days of initiation of support. This
nding confirms what has been previously reported in the
nfant population by our institution (6). In the Mitchell
t al. (6) infant study, ECMO support for 4 days was
ssociated with death and increased risk of morbidity,
articularly sepsis, bleeding, and neurologic sequelae. Re-
overy of ventricular function within 8 days of ECMO
upport has been reported and may become more common
s ECMO and other mechanical support technology
rogress and improve over time.
However, on the basis of our institutional experience
escribed here, consideration could be given to listing for
etransplantation or transition to a VAD if the patient is not
ecannulated within 4 days of initiation of ECMO support
6,18,22). Of course, the clinical situation for each individ-
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ECMO for Primary Graft Failure in Children August 18, 2009:730–7al patient must be carefully considered when making the
ecision to relist for transplantation. The already present
hallenges of shortage of donor supply and increased risk of
ransplantation after support with mechanical assistance
equire that the decision to list for retransplantation should
e reserved for those patients deemed to be good candidates
or this option. Those individuals requiring ECMO after
ransplantation who have evidence of severe neurologic
njury, irreversible organ injury, hyperacute rejection, and
nfection would not be appropriate candidates for retrans-
lantation. The only other factor that correlated with
urvival was a lower donor ejection fraction. This finding
uggests that the use of marginal donors, especially for the
nfant population where donor shortage is a problem, may
ot compromise outcome even if ECMO rescue is necessary
n the early post-transplantation period (24).
Overall, 54% of the patients supported with ECMO were
uccessfully weaned and discharged alive, which is compa-
able to what has been previously reported in the pediatric
opulation (6,16,17). Long-term survival of those surviving
o hospital discharge was excellent, with 100% alive at 3
ears after transplantation.
Although the number of early (within the first year after
ransplantation) acute graft rejection episodes was signifi-
antly increased in the ECMO survivors compared with our
ther transplant recipients, there was no difference in the
otal number of acute graft rejection episodes between these
roups. The number of hemodynamic compromising rejec-
ions per patient also was significantly increased in the
CMO survivors (1.3  1.9 vs. 0.7  1.2 in the overall
ransplant population, p  0.05). In fact, 20% of the
Figure 3 Rejection Episodes for ECMO
Survivors Versus All Transplants
Rejection episodes comparing extracorporeal membrane oxygenation (ECMO)
survivors with all patients transplanted in our program are shown. Early rejec-
tions are defined as rejection episodes during the first year after transplanta-
tion, and very early rejection episodes are defined as occurring during the first
month after transplantation. Hemodynamic compromising rejections are
defined as abnormal hemodynamics documented at catheterization compared
with the patient’s previous baseline and dependence on inotropic support. hem
compr  hemodynamic compromise.CMO survivors presented with at least 1 episode of
Gemodynamically significant rejection requiring inotropic
upport.
The incidence of transplant coronary artery disease in the
CMO survivors (13%) was not increased compared with
ur overall transplantation population (16%). This finding is
omewhat unexpected, because the increased frequency of
arly and hemodynamic compromising rejection in the
CMO survivors are factors that have been associated with
he development of coronary vasculopathy (25,26). This
nding is not related to timing of follow-up because
ransplant coronary vasculopathy in our program is diag-
osed at a mean time of 6.4 years after transplantation, and
he mean follow-up of the ECMO survivors is 8.1 years.
inally, despite increased frequency of early and severe acute
raft rejection in the survivors, the graft function at long-
erm follow-up is normal.
tudy limitations. This study is limited by its descriptive
ature and the small sample of patients.
onclusions
rimary graft failure requiring mechanical circulatory sup-
ort in the early period after transplantation is not uncom-
on in children (9%), and a long ischemic time is a major
isk factor of graft dysfunction. Pediatric cardiac allografts
an be successfully salvaged by ECMO in a reasonable
roportion of patients (54%). Although cardiac arrest before
CMO as well as emergent cannulation did not impact
urvival, these were associated with adverse neurologic
utcome. The duration of cannulation was important in our
eries, with no child in this study surviving ECMO support
or 4 days. If clinical recovery seems unlikely and the
atient is a good candidate for retransplantation, consider-
tion to relist and/or transition to VAD support is reason-
ble if 4 days of support is required. Importantly, long-
erm outcome in those patients supported by ECMO for
rimary graft failure and surviving to hospital discharge was
xcellent, with 100% 3-year survival and normal graft
unction despite an increased number of early rejection and
emodynamic compromising rejection episodes. Therefore,
CMO as a bridge to graft recovery after transplantation
an be used without altering the long-term outcome of this
hallenging group of high-risk post-operative patients.
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